Eribulin

You have access
Eribulin Suppressed Cisplatinum- and Doxorubicin-resistant Recurrent Lung Metastatic Osteosarcoma in a Patient-derived Orthotopic Xenograft Mouse Model
TASUKU KIYUNA, YASUNORI TOME, KENTARO MIYAKE, TAKASHI MURAKAMI, HIROMICHI OSHIRO, KENTARO IGARASHI, KEI KAWAGUCHI, JOHN HSU, MANISH SINGH, YUNFENG LI, SCOTT NELSON, MICHAEL BOUVET, SHREE RAM SINGH, FUMINORI KANAYA and ROBERT M. HOFFMAN

Anticancer Research September 2019, 39 (9) 4775-4779; DOI: https://doi.org/10.21873/anticanres.13661
You have access
The Effects of Eribulin on Breast Cancer Microenvironment Identified Using Eribulin-resistant Breast Cancer Cell Lines
WATARU GOTO, SHINICHIRO KASHIWAGI, YUKA ASANO, KOJI TAKADA, KATSUYUKI TAKAHASHI, HISAKAZU FUJITA, TSUTOMU TAKASHIMA, MASATSUNE SHIBUTANI, RYOSUKE AMANO, SHUHEI TOMITA, KOSEI HIRAKAWA and MASAICHI OHIRA

Anticancer Research August 2019, 39 (8) 4031-4041; DOI: https://doi.org/10.21873/anticanres.13559
You have access
Phase II Clinical Trial of First-line Eribulin Plus Trastuzumab for Advanced or Recurrent HER2-positive Breast Cancer
KOICHI SAKAGUCHI, KATSUHIKO NAKATSUKASA, HIROSHI KOYAMA, MAKOTO KATO, AKIRA SAKUYAMA, TAKAYUKI MATSUDA, NOBUYUKI TSUNODA, IKUYA FUJIWARA, MASAHIDE YAMAGUCHI, HIROKI TANAKA, KAZUYOSHI ONISHI, MIE ONISHI, YUJI YOSHINO, TAKASHI KIKUCHI and TETSUYA TAGUCHI

Anticancer Research July 2018, 38 (7) 4073-4081; DOI: https://doi.org/10.21873/anticanres.12697
You have access
Broad-spectrum Preclinical Antitumor Activity of Eribulin (Halaven®): Combination with Anticancer Agents of Differing Mechanisms
MAKOTO ASANO, JUNJI MATSUI, MURRAY J. TOWLE, JIAYI WU, SHARON MCGONIGLE, MARC HILLAIRET DE BOISFERON, TOSHIMITSU UENAKA, KENICHI NOMOTO and BRUCE A. LITTLEFIELD

Anticancer Research June 2018, 38 (6) 3375-3385; DOI: https://doi.org/10.21873/anticanres.12604
You have access
Eribulin Promotes Antitumor Immune Responses in Patients with Locally Advanced or Metastatic Breast Cancer
WATARU GOTO, SHINICHIRO KASHIWAGI, YUKA ASANO, KOJI TAKADA, TAMAMI MORISAKI, HISAKAZU FUJITA, TSUTOMU TAKASHIMA, MASAHIKO OHSAWA, KOSEI HIRAKAWA and MASAICHI OHIRA

Anticancer Research May 2018, 38 (5) 2929-2938;
You have access
Subtypes of Triple-negative Breast Cancer Cell Lines React Differently to Eribulin Mesylate
KAREN BRÄUTIGAM, KATHARINA MITZLAFF, LISA UEBEL, FRANK KÖSTER, STEPHAN POLACK, MASCHA PERVAN, GUNNAR STEINERT, ACHIM RODY and CORNELIA LIEDTKE

Anticancer Research June 2016, 36 (6) 2759-2766;
You have access
Antimitotic and Non-mitotic Effects of Eribulin Mesilate in Soft Tissue Sarcoma
SATOSHI KAWANO, MAKOTO ASANO, YUSUKE ADACHI and JUNJI MATSUI

Anticancer Research April 2016, 36 (4) 1553-1561;
You have access
Breast Cancer Cell Lines Exhibit Differential Sensitivities to Microtubule-targeting Drugs Independent of Doubling Time
APRIL L. RISINGER, NICHOLAS F. DYBDAL-HARGREAVES and SUSAN L. MOOBERRY

Anticancer Research November 2015, 35 (11) 5845-5850;

Main menu

User menu

Search

Eribulin

Pages